Мақаланы E-mail арқылы жіберу Reserpine Is the New Addition into the Repertoire of AcrB Efflux Pump Inhibitors
- Авторлар: Shaheen A.1,2, Afridi W.A.1, Mahboob S.1, Sana M.1, Zeeshan N.2, Ismat F.1, Mirza O.3, Iqbal M.1, Rahman M.1
-
Мекемелер:
- Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)
- Department of Biochemistry and Biotechnology, University of Gujrat, Hafiz Hayat Campus
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
- Шығарылым: Том 53, № 4 (2019)
- Беттер: 596-605
- Бөлім: Structural-Functional Analysis of Biopolymers and Their Complexes
- URL: https://journal-vniispk.ru/0026-8933/article/view/164029
- DOI: https://doi.org/10.1134/S0026893319040113
- ID: 164029
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Тек жазылушылар үшін
Аннотация
Acriflavine resistance protein B (AcrB) serves as prototype for multidrug resistance (MDR) efflux transporters of resistance nodulation division (RND) superfamily. AcrB has been proven as potential drug target with many synthetic and natural inhibitors have been identified such as those belonging to pyranopyridine, naphthamide and pimozide classes. The plant derived alkaloid inhibitors represented by reserpine has been found to inhibit both ATP binding cassette and major facilitator efflux transporters. In this study we report the reserpine induced inhibition of RND transporter AcrB. The preliminary docking analysis hints that reserpine shares its binding site with ciprofloxacin, a known substrate of AcrB and could possibly act as competitive inhibitor. For in vitro validation, AcrB from Salmonellatyphi was cloned under the control of tac promoter and resulting vector was introduced into E. coli C41(DE3). Under autoinduced conditions, cells overexpressing AcrB transporter were subjected to combined dose of ciprofloxacin and reserpine. The combined exposure resulted in enhanced ciprofloxacin-induced growth inhibition of cells expressing AcrB transporter as compared to control cells transformed with vector of backbone sequence. Time kill analysis further confirmed these findings. To the best of our knowledge, this is first study to show that exposure to reserpine induces inhibition of AcrB. The assay developed in this study allows simple and reproducible detection of substrate/inhibitor effects upon AcrB and related efflux transporters.
Авторлар туралы
A. Shaheen
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE); Department of Biochemistry and Biotechnology, University of Gujrat, Hafiz Hayat Campus
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000; Gujrat, 50700
W. Afridi
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000
S. Mahboob
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000
M. Sana
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000
N. Zeeshan
Department of Biochemistry and Biotechnology, University of Gujrat, Hafiz Hayat Campus
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Gujrat, 50700
F. Ismat
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000
O. Mirza
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences,University of Copenhagen
Email: moazur.rahman@fulbrightmail.org
Дания, Copenhagen, 1165
M. Iqbal
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000
M. Rahman
Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institutefor Biotechnology and Genetic Engineering (NIBGE)
Хат алмасуға жауапты Автор.
Email: moazur.rahman@fulbrightmail.org
Пәкістан, Faisalabad, 44000
Қосымша файлдар
